THOMAS J SMITH, M.D.
Medical Practice at Taos Rd, Altadena, CA
License number
California 75739
Category
Medical Practice
Type
Ophthalmology
Address
Address
240 Taos Rd, Altadena, CA 91001
Phone
(626) 376-4070
Professional information
Systemic Delivery Of Antiviral Agents
US Patent:
2010008, Apr 1, 2010
Filed:
Dec 3, 2009
Appl. No.:
12/630246
Inventors:
Paul Ashton - Newton MA, US
Jianbing Chen - Belmont MA, US
Thomas J. Smith - Altadena CA, US
Jianbing Chen - Belmont MA, US
Thomas J. Smith - Altadena CA, US
Assignee:
pSivida Inc. - Watertown MA
International Classification:
A61K 9/00, A61P 31/12, A61K 31/551, A61K 31/538, A61K 31/496, A61K 31/52
US Classification:
424400, 514220, 5142305, 51425309, 51426338
Abstract:
The systems and methods disclosed herein provide sustained delivery of a therapeutic agent for treating a patient, e.g., human, to obtain a desired local or systemic physiological or pharmacological effect. Method includes positioning the sustained released drug delivery system at an area wherein release of the agent is desired and allowing the agent to pass through the device to the desired area of treatment. In some embodiments, the method is for treating or reducing the risk of retroviral or lentiviral infection. In certain embodiments, the method is for preventing or reducing the risk of mother-to-child transmission of HIV, wherein the therapeutic agent is an antiviral agent.
Dr. Thomas J Smith, Altadena CA - MD (Doctor of Medicine)
Specialties:
Ophthalmology
Address:
240 Taos Rd, Altadena 91001
(626) 376-4070 (Phone)
(626) 376-4070 (Phone)
Languages:
English
Education:
Residency Hospital
University Of Ky Hospital
University Of Ky Hospital
Hmgcoa Reductase Inhibitor-Angiotensin Converting Enzyme Inhibitor Compounds
US Patent:
2007021, Sep 13, 2007
Filed:
Mar 14, 2007
Appl. No.:
11/724149
Inventors:
Tadeusz Cynkowski - Brookline MA, US
Grazyna Cynkowska - Brookline MA, US
Thomas Smith - Altadena CA, US
Grazyna Cynkowska - Brookline MA, US
Thomas Smith - Altadena CA, US
Assignee:
pSivida Inc. - Watertown MA
International Classification:
A61K 31/401, A61K 31/366, A61K 31/22, A61K 31/4184
US Classification:
514423000, 514460000, 514548000, 514394000, 514381000
Abstract:
A compound that contains at least two independently active pharmacological moieties, either covalently conjoined through a physiologically labile linker or ionically associated. One pharmacological moiety is an HMGCoA reductase inhibitor (such as a statin). Another pharmacological moiety is an angiotensin converting enzyme inhibitor.
Methods For Treating Otic Disorders
US Patent:
2007016, Jul 12, 2007
Filed:
Feb 23, 2007
Appl. No.:
11/710045
Inventors:
Paul Ashton - Boston MA, US
Hong Guo - Belmont MA, US
Thomas Smith - Altadena CA, US
Hong Guo - Belmont MA, US
Thomas Smith - Altadena CA, US
Assignee:
pSivida Inc. - Watertown MA
International Classification:
A61F 2/02
US Classification:
424426000
Abstract:
Loss of hearing can be treated by implanting a sustained-release drug delivery device in the inner ear. The slow delivery of medication from the implanted device to the tissues of the ear, including the inner ear, can treat numerous conditions of the ear while avoiding the side effects associated with systemic administration.
Polymer-Based, Sustained Release Drug Delivery System
US Patent:
2012001, Jan 19, 2012
Filed:
Jul 19, 2011
Appl. No.:
13/185664
Inventors:
Jianbing Chen - Wayland MA, US
Paul Ashton - Newton MA, US
Thomas J. Smith - Altadena CA, US
Paul Ashton - Newton MA, US
Thomas J. Smith - Altadena CA, US
Assignee:
pSivida Inc. - Watertown MA
International Classification:
A61F 2/82, A61K 31/58, A61K 31/7064, A61K 31/7068, A61K 31/706, A61K 31/7076, A61K 31/52, A61K 9/00, A61P 29/00, A61P 35/00, A61P 37/00, A61P 33/00, A61P 27/06, A61P 31/00, A61P 31/12, A61K 31/513
US Classification:
623 142, 514274, 514174, 514 49, 514 43, 514 46, 5142633, 51426337, 514 48, 424423
Abstract:
Disclosed is a sustained release system that includes a polymer and a prodrug having a solubility less than about 1 mg/ml dispersed in the polymer. Advantageously, the polymer is permeable to the prodrug and may be non-release rate limiting with respect to the rate of release of the prodrug from the polymer. This permits improved drug delivery within a body in the vicinity of a surgery via sustained release rate kinetics over a prolonged period of time, while not requiring complicated manufacturing processes.